Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The targeted therapies led to an 87% reduction in disease progression or death for newly diagnosed chronic lymphocytic leukemia patients.
Findings suggest “less is more” and “tried and true” may benefit select patients.
Studies underscore continuing role of demographic factors and comorbidities in blood cancer treatment and research.
Targeted therapy combo sent chronic lymphocytic leukemia into deep remission in people with high-risk forms of the disease.
Ivosidenib (Tibsovo) plus chemotherapy may soon be an option for those with leukemia that has an IDH1 mutation.
For those with undetectable minimal residual disease, treatment discontinuation was as effective as staying on Imbruvica.
The drug targets cancer’s survival proteins, making them more vulnerable to treatments that cause cancer cells to self-destruct.
The regimen is approved for adults age 75 or older and those who cannot use intensive induction chemotherapy.
Imbruvica, Calquence and Venclexta demonstrate good results in combination regimens.
In a recent study, Dana-Farber scientists and others uncovered a key part of why some patients eventually become resistant to Venclexta.
Targeted therapy combination reduced the risk of disease progression or death by 65% in a randomized study.
Study found Venclexta plus Gazyva (obinutuzumab) delayed disease progression in previously untreated patients.
Imbruvica plus Gazyva is the first chemotherapy-free regimen for chronic lymphocytic leukemia.
Researchers believe their greater understanding of leukemia stem cells will lead to more treatment options for people with the blood cancer.
Researchers called the results of treatment using Venclexta (venetoclax) and Vidaza (azacitidine) “remarkably impressive.”
Imbruvica-based treatment may also work better than intensive chemotherapy for younger patients.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.